...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacogenomics >Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics.
【24h】

Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics.

机译：对利培酮和其他较新的非典型抗精神病药反应的药物遗传学研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Risperidone and other newer atypical antipsychotics are becoming the mainstay for schizophrenia treatment. Recent studies suggest that the 5-hydroxytryptamine receptor 2A (5-HT2A) gene (HTR2A) T102C and G-1438A polymorphisms may influence treatment response of risperidone or olanzapine for schizophrenia's negative symptoms (e.g., blunted affect and social withdrawal). In addition, the HTR6 T267C polymorphism has been linked to risperidone response for positive symptoms (delusions and hallucinations). The dopamine D2 receptor (DRD2) Ser311Cys polymorphism may also play a role in determining risperidone efficacy for positive, negative and cognitive symptoms, the DRD2 Ins-A2/Del-A1 diplotype may predict better risperidone response, and the DRD3 Ser311Cys variant may affect general treatment response of several atypical agents. Although investigators have started to explore genetic effects on cognitions of schizophrenia patients receiving antipsychotics, future larger sized pharmacogenetic studies on both psychotic symptoms and cognitive functions are warranted.
机译：利培酮和其他较新的非典型抗精神病药正成为精神分裂症治疗的中流tay柱。最近的研究表明，5-羟色胺受体2A（5-HT2A）基因（HTR2A）T102C和G-1438A多态性可能影响利培酮或奥氮平对精神分裂症的负面症状（例如钝痛和社交退缩）的治疗反应。此外，HTR6 T267C多态性与利培酮对阳性症状（妄想和幻觉）的反应有关。多巴胺D2受体（DRD2）Ser311Cys多态性也可能在确定利培酮对阳性，阴性和认知症状的疗效中起作用，DRD2 Ins-A2 / Del-A1双倍型可能预测更好的利培酮反应，而DRD3 Ser311Cys变异可能影响几种非典型药物的治疗反应。尽管研究人员已开始探索遗传学方法对接受抗精神病药治疗的精神分裂症患者的认知，但仍需对精神病症状和认知功能进行更大规模的药物遗传学研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号